Skip to main content
Equibles
ABEO logo

ABEO · Abeona Therapeutics Inc. · Metrics

Track ABEO — free

Use ABEO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABEO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.49 -0.31 (-5.27%)
Russell 2000 member Rebalance outlook locked
Market Cap
$331.10M
Shares
57.18M

ABEO metrics

69 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.79
Market cap
$331.10M

Price action

20 metrics
Price change (1W)
-2.2%
Price change (30D)
-21.5%
Price change (3M)
+7.3%
Price change (6M)
+13.8%
Price change (YTD)
+11.0%
Price change (1Y)
-12.7%
Trailing year
Price change (5Y)
—
52-week high
$7.46
52-week low
$4.17
Change from 52-week high
-21.6%
Change from 52-week low
+40.3%
Annualized volatility
54.1%
Annualized volatility (3M)
55.2%
Beta
1.5
RSI (14D)
40.9
Price vs SMA 50
-9.0%
Price vs SMA 200
+6.3%
Avg volume (3M)
1.39M
Relative volume
0.6
Average dollar volume
$8.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
57.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.3×
reciprocal yield 12.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
13.4×
reciprocal yield 7.4%
P / book
2.7
reciprocal yield 37.3%
FCF yield
-23.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
73.7%
Operating margin
-1,536.9%
Trailing 12 months
Net margin
1,223.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$83.61M
Net income (TTM)
−$62.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.89

Growth

11 metrics
Revenue growth YoY
+2,745.0%
Year over year
Net income growth YoY
-118.6%
Revenue (TTM)
$25.52M
Trailing 12 months
EPS growth YoY
-120.5%
Shares change YoY
-14.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+60.3%
Revenue CAGR (5Y)
-10.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-49.1%
Return on assets
-35.0%
Debt / equity
0.1
Current ratio
6.6
EBITDA (TTM)
−$80.81M
Free cash flow (TTM)
−$81.53M
Quick ratio
6.4
Interest coverage
-25.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$131.84M
Latest balance sheet
Cash & equivalents
$56.23M
Total assets
$179.51M
Total debt
$14.99M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$76.44M
Capital expenditures (TTM)
$5.09M
R&D (TTM)
$25.50M
SG&A (TTM)
$73.43M
Stock compensation (TTM)
$11.57M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
126
13F filer change QoQ
+17
Institutional ownership
71.9%

Short interest

3 metrics
Short interest
25.0%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.08M
Insider-sentiment score
14 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 318306 CUSIP 00289Y206 13F (30d) 83 filings 83 filers Visit website Investor relations